No retraction, correction or concern found when last checked on Oct 27, 2026.

Gene Therapy Tools for Brain Diseases

Selene Ingusci, Gianluca Verlengia, Marie Soukupova and 2 more

Frontiers in Pharmacology · 2019 · Review · CC BY

doi:10.3389/fphar.2019.00724

Abstract

Neurological disorders affecting the central nervous system (CNS) are still incompletely understood. Many of these disorders lack a cure and are seeking more specific and effective treatments. In fact, in spite of advancements in knowledge of the CNS function, the treatment of neurological disorders with modern medical and surgical approaches remains difficult for many reasons, such as the complexity of the CNS, the limited regenerative capacity of the tissue, and the difficulty in conveying conventional drugs to the organ due to the blood-brain barrier. Gene therapy, allowing the delivery of genetic materials that encodes potential therapeutic molecules, represents an attractive option. Gene therapy can result in a stable or inducible expression of transgene(s), and can allow a nearly specific expression in target cells. In this review, we will discuss the most commonly used tools for the delivery of genetic material in the CNS, including viral and non-viral vectors; their main applications; their advantages and disadvantages. We will discuss mechanisms of genetic regulation through cell-specific and inducible promoters, which allow to express gene products only in specific cells and to control their transcriptional activation. In addition, we will describe the applications to CNS diseases of post-transcriptional regulation systems (RNA interference); of systems allowing spatial or temporal control of expression [optogenetics and Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)]; and of gene editing technologies (CRISPR/Cas9, Zinc finger proteins). Particular attention will be reserved to viral vectors derived from herpes simplex type 1, a potential tool for the delivery and expression of multiple transgene cassettes simultaneously.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Even if scientific research has made great progress over the last decade in identifying pathogenic mechanisms and treatment strategies, neurological disorders affecting the central nervous system (CNS) are still incompletely understood. The majority of these disorders lack a cure or, at least, reasonably effective treatments. Reasons are certainly multifold and include the complexity of the CNS, the limited regenerative capacity of the tissue, and the difficulty in conveying conventional drugs to the organ across the blood–brain barrier (BBB). Neurons, the principal cells of the nervous tissue, are not only morphologically and physiologically heterogeneous, but also strictly organized to form complex circuits. Neural stem cells ensure only a limited replacement of only specific neuronal types. The BBB expresses a selective permeability for molecules that possess a limited range of molecular weight and lipophilicity, preventing the entry of large-molecule drugs and of the majority of small-molecule drugs.

2In this context, gene therapy is emerging as an attractive therapeutic option, because it can result in a stable or inducible expression of therapeutic gene(s), and can allow a nearly specific expression in target cells. Although much remains to be done before it becomes routine practice, the potential of gene therapy for the treatment of CNS diseases is amply demonstrated by numerous preclinical and clinical studies.

3A large part of the work needed to finally reach the stage of clinical application consists in the refinement of the tools needed for a safe, targeted, and regulated gene delivery. In this review, we will discuss the most commonly used gene therapy tools for delivery in the CNS and the strategies that can be employed for regulating therapeutic gene expression.

Gene Therapy

4The idea behind gene therapy derives from an assumption of great simplicity: by introducing into the cells the “correct” copy of a defective gene whose malfunction causes a disease, its product, a functional protein, will be able to revert the pathological phenotype. This assumption may be correct for monogenic diseases caused by alterations in the coding sequence or in regulatory regions of a single gene, and if these alterations lead to loss of function without production of a pathogenic protein. However, many diseases have a pattern of multiple altered genes. Moreover, the regulation of gene expression is often complex and difficult to reconstruct. According to a new, broader definition, all drugs that contain an active substance that includes or consists of a recombinant nucleic acid (DNA or RNA), administered to a human being for the purpose to adjust, repair, replace, add, or remove a gene sequence, can be defined gene therapy.

5The introduction of a functional gene, called transgene, within the cell nucleus is a complex operation that starts with the choice of a delivery system (gene therapy vector). A good vector should fulfill many requirements:

6Manipulation: the vector should be easily manipulated for recombination and propagation in suitable hosts.

7High cloning capacity: the vector should allow the introduction of one or more genes and regulatory sequences that guarantee the desired spatial and temporal restriction of transgene expression.

8Minimal invasiveness: the vector should not cause uncontrolled or undesired alterations of the host genome. The integration of a vector into the cellular genome can induce insertional mutagenesis.

9Selectivity for the cellular target: the transgene should be expressed exclusively in the target cells.

10Absence of immunogenicity: the vector should not contain genes that induce immune responses or other factors that may be harmful to the body.

11Stability over time: the vector should be transferred unaltered in the cell progeny and/or must allow a correct and prolonged expression of the transgene(s).

12Available gene therapy vectors belong to two broad categories: viral and nonviral vectors.

Nonviral Vectors

13Nonviral vectors offer some advantages, like reduced pathogenicity, low cost, and simple production techniques. However, DNA delivered by nonviral vectors must overcome a number of extracellular and intracellular barriers, limiting the efficiency of transfection. In fact, the transfection efficiency is limited by the premature release of the genetic material into the bloodstream and its subsequent degradation by serum nucleases when administered intravenously, while the endocytosed DNA is in large part degraded along the endosome/lysosome pathway before it reaches the nucleus.

14In addition to direct injection and microinjection of DNA into the nucleus, physical methods and chemical carriers have been developed to improve delivery of naked DNA to cells and tissues. Commonly used nonviral delivery tools are cationic polymers and cationic lipids, whose efficiency is dependent on cationic charge, saturation, and linker stability. Several strategies have been explored to increase the stability of DNA in the circulation. Polyethylene glycol (PEG) is one example. Another approach is the use of bio-responsive polymers that exploit the chemical–physical properties of the biological microenvironment (pH, presence of reducing agents, etc.) to promote the release of the genetic material exclusively intracellularly. Other tested strategies are acetyl bonds, which degrade at the pH of the endosomal environment, or disulfide bridges, which are reduced in the cytosol.

Viral Vectors

15Independent of their origin, order, and family, viruses have evolved very fine strategies to reach and penetrate specific cellular targets. Their use in gene therapy lies in their innate ability to deliver and express genetic information into host cells. Replication-defective viral vectors commonly derive from wild-type viruses in which the therapeutic gene(s) are inserted into the viral genome by replacing the “wild” genes essential for the lytic cycle, thereby preventing the virus to replicate and exert cytotoxic effects in target cells. These genes, however, can be replaced by trans-acting factors through the development of specific cell lines or the use of helper viruses during the manufacturing process. Among all viral vectors, the most characterized and used for targeting the CNS have been derived from retroviruses, adenoviruses, adeno-associated viruses, and herpes simplex viruses. These vectors differ in payload capacity, cell tropism ( Table 1 ), and ability to integrate into the host genome, which may affect the duration of transgene expression. Advantages and disadvantages, potential CNS application, and side effects for each of the above-mentioned vectors will be briefly discussed below.

Retroviral/Lentiviral Vectors

16The Retroviridae family consists in a broad range of small RNA viruses whose common feature is to replicate through a DNA intermediate. γ-Retrovirus and lentivirus belong to this family. The former is more suitable for ex vivo gene therapy applications, because it does not efficiently infect nondividing cells and because it is difficult to reach high viral titers. The latter infects both proliferating and quiescent cells, ensuring long-term gene expression in the absence of inflammatory responses.

17While the lentiviral integrative nature ensures stable and persistent expression of the transgene, it also entails the risk of insertional mutagenesis. However, gene editing allowed to develop safe lentiviral vectors with specific integration sites. To increase the safety of lentiviral vectors, the viral genome can be split in multiple plasmids, thereby making recombinant virus generation very unlikely. In addition, envelope glycoproteins (gp) can be pseudotyped to redirect viral particles to specific targets.

18Since lentiviral vectors transduce neurons effectively, they have been tested for the treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Adenoviral Vectors

19Adenoviruses are linear double-stranded DNA viruses with a genome size of 35–40 kb encoding approximately 30–40 genes. There are 100 serotypes of adenovirus, 57 of which have the potential to infect humans. These are divided into seven subgroups, A to G, that differ in cellular tropism. The most frequently utilized for gene therapy are types 2 and 5, both belonging to subtype C.

20Adenoviral vectors transduce efficiently dividing and nondividing cells, with no risk of integration in the host cell genome. Their main limitations are high immunogenicity; transient transgene expression (from 2 weeks to a few months); and high risk of cytopathic effects. New generations of adenoviral vectors partially overcome these limitations.

21Adenoviral vectors have been widely studied for the treatment of tumors. In addition, preclinical studies have been conducted in rodent models of PD and Huntington disease (HD).

Adeno-Associated Vectors

22Adeno-associated viruses (AAVs) are small, non-enveloped, single-stranded DNA viruses belonging to the Parvoviridae family. Despite the size limitation, they are considered the most promising vehicle for gene therapy targeting the CNS because they are clinically safe and effective in transducing dividing and quiescent cells, while capable of establishing a long-term transgene expression. More than 150 clinical trials with a good safety profile and significant clinical benefit in many genetic diseases used AAV vectors. The AAV genome contains only three genes, replication (rep), assembly (aap), and capsid (cap), necessary for viral replication, integration, and packaging. AAVs can persist in the host cell in an episomal state, only a small fraction integrating into the host cell genome.

23More than 12 different AAV serotypes have been isolated. Each of these has specific features, including: differences in cellular tropisms, depending on different capsid surface proteins; differences in transduction efficiency; and differences in ability to evade the host immune response and to cross the BBB. Many serotypes transduce efficiently neurons and glial cells. Refinement of AAV vector features and increased brain uptake have been obtained by pseudotyping approaches, like mixing of capsids and genome from different viral serotypes; insertion of peptide motifs from phage libraries; or enrichment of the capsid through random incorporation of peptide motifs.

24Owing to the small sized genome, AAV vectors are capable of accommodating less than 5 kb of exogenous DNA. However, strategies are under development for delivering larger genes. One approach could be using truncated forms of genes and/or promoters that maintain the properties of their full-length counterpart. An alternative strategy has been developed by taking advantage of the AAV innate ability to undergo a genomic intermolecular recombination that can give rise to head-to-tail DNA concatamerization. In this context, the DNA sequence of an oversized expression cassette can be split and packaged in two or even three independent AAV vectors. Upon concomitant infection of the host, these multiple vectors may give rise to DNA concatamers, which can reconstitute the whole cassette. The efficiency of this multiple-vector strategy is obviously significantly lower than the single-vector strategy, and attempts are ongoing to improve the situation.

25The therapeutic potential of AAV-based gene therapy has been tested in many different neurological disorders.

Herpes Simplex Vectors

26The first Herpesvirus vector has been derived from Herpes Simplex Virus type 1 (HSV-1), an enveloped ubiquitous virus with a double-stranded linear DNA genome. Hallmarks of HSV-1 are the short replication cycle and the ability to travel via retrograde axonal transport from the primary infection site to the sensory neurons of the CNS, where it establishes a life-long latency in an episomal form. Since then, three types of HSV-1 based vectors have been developed: replication-competent, replication-defective, and amplicon vectors. Replication-competent vectors are used in oncology for their ability to complete a lytic cycle in the presence of permissive cellular environments. Replication-defective and amplicon vectors are tested as gene transfer tools for the CNS.

27The large genome (152 kb) of HSV-1 encodes about 80 genes, half of which can be removed to make room for up to 50 kb of foreign DNA in the case of replication-defective vectors and up to 150 kb for amplicon vectors. HSV-1 vectors maintain high infectivity, ability of both retrograde and anterograde transport, and potential to establish a latent infection in the episomal form. Traditional limitations in their application are residual toxicity towards the infected cells and the short-term expression of the transgene due to rapid silencing mechanisms.

New HSV-Based Vectors for Delivering Multiple Expression Cassettes

28Disorders of the CNS are often not a result of single gene mutation or of a single molecular mechanism but have instead a multifactorial origin. As a result, the therapeutic gene(s) and/or the regulation sequence to be delivered very often exceed the payload capacity of viral vectors. HSV-1 vectors represent an attractive solution for this issue, because of their large genomic size and capacity to host large amounts of foreign DNA. As noted above, however, the first generations of replication-defective HSV-1 vectors were hindered by highly significant limitations, including toxicity and short-term expression of the transgenes. Many recent studies have been aimed to solve these problems.

29The HSV productive cycle is characterized by a temporally regulated cascade of gene expression, during which three distinct classes of transcripts are expressed in a sequential manner. The immediate early genes (IE or α) are first expressed, followed by the early (E or β) and late (L or γ) genes. IE genes are required not only for establishment of a lytic reproductive cycle, but also to overcome innate immune responses, to block cell division, and to prevent host cell apoptosis and epigenetic repression of viral genes. The engineering of mutant HSV-1 vectors devoid of α genes shuts off viral replication and remarkably reduce cytotoxicity. Deletion of two IE genes, ICP4 and ICP27, gave rise to the first (ΔICP4) and second (ΔICP4/27) generation of HSV-1 vectors. These early generations were able to establish a long-term expression without the ability to reactivate, but the residual presence of ICP0 was responsible of cytotoxic effects in transduced cells. The consequent deletion of ICP0 gave rise to a third generation of vectors that were devoid of toxicity but displayed short-term expression of the transgene. To overcome this hurdle, a novel generation of HSV-1 vectors ( Figure 1 ) was engineered by inserting the transgene expression cassette into the viral latency-associated transcript locus, a genome region that is protected from silencing during latency by the presence of insulator sequences (CTRL) that act as boundary elements to shield the locus against epigenetic modifications. This new generation of highly defective vectors offers a large payload capacity while displaying no sign of toxicity upon in vitro infection of diverse cell types. The in vivo injection of this new class of HSV-based vectors into different brain regions of naive rats yielded a robust and persistent (up to 6 months) neuron-specific expression of transgenes inserted in the ICP4 locus, without evidence of toxicity or inflammatory cell infiltration, suggesting that the ICP4 locus may be an option to achieve a sustained and prolonged transgene expression in neurons. A further modification of the viral backbone (the deletion of the UL41 gene that may contribute residual toxicity) further improved the levels of transgene expression. UL41-deleted vectors displayed an improved, long-lasting and neuron-specific transgene expression without any evidence of toxicity. Recently, in order to overcome the rapid transcriptional repression of transgenes cloned outside the ICP4 locus, the backbone was further engineered with specific cellular anti-silencing elements, inserted to prevent the formation of heterochromatin at the transgene promoter level. Different types of anti-silencing elements were evaluated, but the most effective in increasing neuronal transgene expression in both in vitro and in vivo assays was A2UCOE. In conclusion, these new replication-defective backbones seem to hold the features and the flexibility of options needed for gene therapy applications in the CNS.

30Amplicon vectors ( Figure 2 ) are the other promising class of HSV-1-based vectors. Amplicons maintain all structural, immunological, and host range properties of the wild-type virus, but only two elements, the viral origin of replication (ori) and the capsid packaging sequence (pac), are retained from their original genome, the other part consisting of a concatemer repetition of the foreign DNA. The major advantage of this gene transfer tool is that the total deletion of viral genes allows the insertion of up to 150 kb of exogenous DNA. The number of concatameric repeats depends on the size of the expression cassette, i.e., short sequences allow the insertion of more copies of the gene of interest. Furthermore, the complete absence of all viral genes strongly reduces the risk of reactivation, complementation, or recombination with latent HSV-1 genomes. The downside is that amplicon propagation is rather difficult, because cell lines able to complement all viral proteins in trans are not available. Therefore, first generation of amplicon vectors was propagated by transfection of amplicon plasmids into cells, which were then superinfected with an HSV-1 helper virus. Unfortunately, this approach leads to a significant (about 1%) contamination with helper virus. A promising alternative is the use of the LaL helper virus, in which the packaging sequence can be deleted by Cre-lox specific-site recombination, reducing the helper contamination to 0.05–0.5%. Despite the fact that amplicon vectors have been widely used for exploring the mechanisms of CNS function, only few studies have focused on their use for gene therapy. Recently, ultrapure amplicons produced using a highly defective helper virus have been employed to silence brain-derived neurotrophic factor (BDNF) expression in an animal model of epilepsy. Apart from the production difficulties, amplicon vectors suffer from a relatively short-time expression of the transgenes in the living organism. Most likely, the presence of bacterial sequences in the amplicon genome causes transgene silencing by forming inactive chromatin. Therefore, the current research in this field focuses on the development of new, helper virus independent production techniques and on means to obtain long-term expression of the transgene.

Genes Encoding Therapeutic Proteins

31The question that comes together with the development of suitable vectors for gene transfer in the CNS is which genes to transfer. The first, most obvious option is genes encoding a therapeutic protein. This may be the correct copy of a defective gene whose malfunction causes the disease, but also a gene encoding a therapeutic protein that could not be peripherally administered, not being able to cross the BBB. In this last instance, the protein could be diffusible (i.e., produced and secreted by the infected cell) to produce a by-stander effect in adjacent cells.

32Apart from genes encoding therapeutic proteins, however, there are other cargo options for CNS gene therapy vectors, like gene editing, chemogenetic, and optogenetic tools.

Gene Editing Tools

33A step forward was made in gene therapy with the development of gene editing tools that can correct genetic defects directly in the host DNA. These tools generate a double strand break (DSB) at a precisely desired location, and the break allows to take advantage of the fine strategies that cells have evolved to detect and repair DNA damage. The DSB can lead to gene disruption by non-homologous end joint, or gene addition or repair by homologous recombination using an exogenously supplied repair template. The most promising gene editing system is the Clustered Regularly Interspaced Short Palindromic Repeats/Cas (CRISPR/Cas) system. The delivery platforms described in this review are obviously essential for this new and powerful therapeutic tool.

Chemogenetic and Optogenetic Tools

34The complexity of the mammalian brain has no comparison: dozens of billions of interconnected neurons, with complex morphology and circuit interaction, capable of exchanging electrical signals with a precise temporal scan in the order of milliseconds. A great challenge is to develop the ability to control only one type of cell in the brain without affecting others. Electrical, physical, pharmacological, and genetic methods are traditionally used to manipulate cells and synapses. However, all these methods lack temporal and spatial resolution and can cause stimulation, inhibition, or inactivation of off-target cells and processes. To overcome these limitations, new genetic tools referred to as “chemogenetic” and “optogenetics” have been developed.

Designer Receptors Exclusively Activated by Designer Drug

35Chemogenetics is the processes in which proteins are engineered to interact specifically with a small molecule. Different proteins involved in CNS disorders have been engineered to this aim, including enzymes, and G protein-coupled receptors (GPCRs;; ). The latter include allele-specific GPCRs, Receptors Activated Solely by a Synthetic Ligand (RASSLs; ), and Designer Receptors Exclusively Activated by Designer Drugs (DREADDs; ). The first chemogenetically engineered GPCR was the β-adrenergic receptor. Following mutations at the β-adrenergic receptor binding site, the responsiveness to the natural ligand disappeared and a new specificity was obtained to ketonic and catechol esterase agonists. Several years later, RASSLs receptors were developed, based on human κ-opioids, that lost their affinity for the endogenous peptide ligand (dynorphin) and gained specificity for small and safe drugs such as spiradoline.

36Together with optogenetics, the DREADDs technology is currently the most used tool for in vivo manipulation of the activity of genetically defined neuronal populations. An example of DREADDs technology is the use of modified muscarinic receptors, hM3Dq for stimulation and hM4Di for inhibition, which have lost their affinity for endogenous acetylcholine, but can be activated by a synthetic ligand (clozapine-N-oxide, CNO) that crosses the BBB. Compared to previous techniques, chemogenetics based on DREADDs confers the ability to regulate and manipulate in a non-invasive manner the activity of specific neuronal circuits. Combined with the set of gene therapy tools described above, DREADDs can be delivered and almost selectively expressed in the neuronal subpopulation of interest, for example serotoninergic or glutamatergic neurons.

37DREADDs are useful tools for basic scientific research but may also refine gene therapy approaches for neurodegenerative disorders in which changes in neuronal activity play an important role. Neuronal hyperactivity and hyperexcitability of the cerebral cortex and hippocampus are common features of epilepsy and AD. On demand attenuation of seizures was achieved after delivery of AAV vectors carrying the hM4Di receptor under the control of the CamkIIα promoter. Moreover, transient cholinergic-specific stimulation led to a striking improvement in motor scores in a rodent model of PD including gait and postural abnormalities.

Optogenetic Approaches

38The term optogenetics indicates a methodology that allows to control the activity of specific neurons within intact neuronal circuits. The idea of using the light as a tool to control neuronal function was originally put forward by Francis Crick. In the 1970s, biologists discovered that some microorganisms generate proteins that, in response to visible light, regulate the flow of charges across the membranes. These proteins, termed opsins, are photosensitive trans-membrane proteins that, when illuminated at defined frequencies, induce transmembrane ion fluxes and, thereby, changes in the electrical activity of the cell. There are two major classes of opsins, which differ in sensitivity to light and absorption properties, and cause activation or inhibition of neurons:

39Channelrhodopsin (ChR): a blue light activated cation-channel from Chlamydomonas reinhardtii, used to excite neurons;

40Halorhodopsin (NpHR): a yellow light activated chloride-pump from Natronomonas pharaonic, used to inhibit neurons.

41Through viral vectors, the gene coding for an opsin can be integrated into target neurons, leading to expression of the opsin protein on the membrane. A nearby source of light, set on the right wavelength and frequency, can then interact with it, activating or inhibiting neuronal activity. The introduction of mutations to existing opsin variants allowed to overcome certain problems associated with light delivery. For example, the ChR chETA mutant displays faster channel closing and increased temporal control. The C1V1 mutant can be excited by longer wavelengths, allowing deeper penetration of the tissue. At the same time, light delivery tools have been improved and optimized for in vivo studies.

42The use of optogenetics as therapeutic tools for neurological disorders has been investigated in PD, AD, and epilepsy. Enhanced excitation of pyramidal neurons is a common feature of many forms of epilepsy, and its control may lead to therapeutic effects. NpHR delivery into these neurons promptly and dramatically reduced seizures upon light stimulation. Enhancing inhibitory activity of interneurons via transfection of the excitatory opsin ChR also resulted in reduced seizure frequency and severity upon light stimulation. Optical inhibition of the subthalamic nucleus in PD models significantly improved akinesia and ameliorated levodopa-induced dyskinesia.

Regulation of Gene Expression

43As previously mentioned, precise regulation of gene expression is essential for any gene therapy approach. A good gene regulation system should be adjustable over a broad dose range; should exert no off-target effect; does not influence endogenous gene expression; should be region or cell speciﬁc; and should allow to quickly turn off and on transgene expression. Regulation of gene expression, in terms of increasing or decreasing levels of a specific gene product or in terms of directing the information to a desired target tissue, can occur at different levels. In this section, we will discuss the gene regulation strategies currently used in gene therapy, e.g., at the transcriptional level, by means of tissue specific and inducible promoters; and at post-transcriptional level, by means of RNA interference techniques.

Transcriptional Level: Tissue Specific and Inducible Promoters

44Regulation or RNA transcription depends on the euchromatin and heterochromatin state and on the interaction of transcription factors with regulatory DNA elements, including promoters ( Table 2 ), insulators, enhancers, and silencers.

Ubiquitous and Tissue-Specific Promoters

45Promoters are the main elements that determine the strength and cellular specificity of gene expression. Ubiquitous and constitutive promoters are strongly active in a wide range of cells and tissues. Therefore, ubiquitous expression promoters are used in gene therapy when targeting a specific cell type is not required, i.e., transgene expression is sought in the broadest possible spectrum of cells. Promoters frequently employed to drive exogenous DNA expression in a non-cell specific manner include cytomegalovirus (CMV) immediate-early; enhancer/chicken-β actin (CAG); human ubiquitin C (UBC); simian virus 40 early (SV40); human elongation factor 1α (EF1α); and mouse phosphoglycerate kinase 1 (PGK). Previous works have described the relative strengths of commonly used transcriptional regulatory elements both in vitro and in vivo. CAG, EF1α, and CMV are the strongest among those analyzed. However, the CMV promoter exerts variable results, being very strong in some cell types and rather weak in others.

46The use of cell-type specific promoters may be useful for confining the transgene expression to a specific cell type. Limitations for their use in gene therapy include their low level of expression and their large genomic size. In principle, however, specifically labeling a population of neurons or glial cells might allow to achieve the therapeutic goal without incurring in off-target effects. The synapsin-1 (Syn1) and the neuron-specific enolase (NSE) promoter are used for their ability to selectively drive transgene expression in neurons, while the glial fibrillary acidic protein (GFAP) promoter results in astrocyte-specific expression. Transgene expression can be specifically targeted to oligodendrocytes by the myelin basic protein (MBP) or the human myelin associated glycoprotein (MAG) promoter, the latter in both a full-length and a truncated version. High level of microglial cells specificity can be obtained with the F4/80 promoter.

47The balance between excitatory and inhibitory signals, basically the equilibrium between glutamatergic and GABAergic neurotransmission, can be often disrupted in diseases like epilepsy. Therefore, targeting specifically GABAergic or glutamatergic neurons may be needed for many applications. The phosphate-activated glutaminase (PAG) or the vesicular glutamate transporter (vGLUT) promoter ensures ∼90% glutamatergic neuron-specific expression, whereas the glutamic acid decarboxylase (GAD) promoter ensures ∼90% GABAergic neuron-specific expression.

48Promoters are not the only elements necessary for transcriptional regulation. Combining regulation elements of different kinds such as promoters, enhancers, introns, and polyadenylation signals by creating hybrid sequences allows modulation of the expression levels. The levels of transgene expression may be strongly influenced by a rapid epigenetic silencing of the exogenous promoters. To protect the promoter and the whole expression cassette from heterochromatization, insulator elements have been tested for their ability to maintain transcriptionally competent whole portions of DNA, regardless of the tissue type and the integration site. As reviewed extensively elsewhere, these protective elements are divided into enhancer-blocking insulators, whose function is mediated by the CTCF-binding factor and barrier insulators, whose mechanism of action is less known. The first well-characterized vertebrate insulator derived from the chicken β-globin locus associated with a constitutive DNAse I, the hypersensitive site-4 called cHS4. cHS4 exhibits both enhancer-blocking activity and barrier activity. Many studies concerning the delivery of retroviral vectors showed that the inclusion of the cHS4 element allows to increase transgene expression. Others, such as the ubiquitous chromatin opening element (UCOE) derived from the human HNRPA2B1-CBX3 locus (A2UCOE), show increased stability of transgene expression due mainly to resistance to DNA methylation-mediated gene silencing. Other elements to consider include enhancer elements, whose insertion significantly affects the expression levels of the transgene. Often used in genetic engineering is the CMV enhancer (eCMV), whose presence in cultured cells strongly increases the expression of the transgene when under the control of PDGF-β (platelet-derived growth factor-β) promoter, conferring efficient neurons specific gene expression.

Inducible Promoters

49For many applications, it is desirable to modulate the expression of the transgene by switching it on or off. Unregulated long-term overexpression of certain transgenes can cause side effects in the CNS, such as aberrant reorganization of the tissue and activation of compensative pathways and/or inactivation/saturation of activated pathways. A finer regulation can be achieved using inducible promoters. These systems are obtained by incorporating in the vector (or in a separate vector) a cassette driving the constitutive expression of a transcription factor (transactivator) able to activate or block the expression of the transgene depending on the availability of a soluble molecule that can be administered systemically.

The Tet On/Tet Off Regulation System

50A commonly used regulation system is based on the mechanism of tetracycline resistance in prokaryotes. Two variants are available ( Figure 3 ), both relying on tetracycline to deactivate (Tet-off system) or activate gene expression (Tet-on). In the Tet-off system, the transgene is under the transcriptional control of the tet operator (tetO), a fragment of DNA responsive to the transactivator tTA, composed of the tet-repressor (tetR) fused to the VP16 viral protein transactivation domain. The transgene is expressed only when tTA binds tetO in the absence of doxycycline, an analogue of tetracycline. Otherwise stated, the presence of tetracycline or its analog in the culture medium or in the organism reversibly induces the transactivator to detach from the operator, causing the transgene to “switch off.” The Tet-on system was developed by inducing random mutations in the tetR. One mutation resulted in a protein with opposite function, which was named reverse tet-repressor (rtetR). This mutant protein, when fused to the VP16 transactivation domain (reverse transactivator, rtTA), drives transgene expression only in the presence of doxycycline.

51Tetracycline-based regulatory systems hold a great potential for gene therapy applications. They ensure rapid in vivo induction or inhibition kinetics and low toxicity—tetracycline and its derivatives have been used for decades for their antimicrobial activity. Limitations are mainly due to high basal transgene expression, in particular when the expression is driven by a constitutive promoter. Recently, a second generation of tetracycline-regulated system containing a shortened CMV minimal promoter was found to increase regulation efficiency and display low basal expression. Modifications in the tetO sequence (TRE-tight1) driven by an NSE were found to improve gene expression efficiency and to reduce the leaky basal transcription.

52For CNS applications, it is necessary to obtain adequate concentrations of doxycycline in the brain, which is difficult due to the limited ability of this drug to cross the BBB. However, new rtTA variants containing mutations in the doxycycline contact domain enhance sensitivity to doxycycline, resulting in a reduction of the concentrations required for transgene regulation. The majority of CNS applications involving the tetracycline-regulated system used viral vectors for the construct delivery, e.g., lentiviruses, adenoviruses or AAVs, and resulted in a tightly regulated gene expression. For example, the lentiviral vector-mediated delivery of GDNF regulated by a Tet-on system in a PD rat model resulted in a precise regulation of transgene expression and in neuroprotection of nigral DA neurons.

The Rapamycin Regulation System

53The rapamycin regulation system is based on the interaction between two inactive transcription factors, a DNA binding domain and a DNA transcriptional activation domain. Each transcription factor is fused to heterologous binding domains for rapamycin. The DNA binding domain is fused to three copies of the FK-binding protein (FKBP), while the DNA activation domain is fused to a lipid kinase, FKBP12 rapamycin-associated protein (FRAP). Rapamycin allows their interaction, thus forming an active, heterodimeric transcription factor that drives the expression of the transgene ( Figure 4 ).

54This system holds many of the features required for clinical use. First, rapamycin is a clinically approved drug, used as an antifungal and antitumor molecule that can be administered orally and can cross the BBB. Second, the system ensures low basal expression of the transgene in the absence of rapamycin, but can be triggering by low doses of the drug. The limitations are mainly related to the immunosuppressive properties of rapamycin, dependent on blockade of the mTOR signaling pathways. The rapamycin analogues “rapalog” (e.g., AP21967) were engineered by adding substituents that prevent the binding to mTOR.

55A limited number of studies tested this system in the CNS by delivering it through lentiviral, AAV, and HSV-1-based vectors. A dose-dependent response to rapamycin was observed after delivering into the rat striatum a rapamycin regulated AAV2-GDNF vector, by evaluating GDNF biogenesis and accumulation under various rapamycin dosing regimens. In addition, chronic administration with clinically compatible regimens of rapamycin provided GDNF protein levels similar to those reported to be neuroprotective in PD animal models.

Post-Transcriptional Gene Regulation

56The term “post-transcriptional gene regulation” refers to approaches designed to enhance degradation or block translation of a target mRNA. The prototypical example is RNA interference (RNAi, Figure 5 ), a physiological and evolutionarily conserved gene silencing mechanism normally present in eukaryotic cells, which is mediated by a group of noncoding small RNAs. Although many types of small RNAs have been identified, the main classes seem to be short interfering RNAs (siRNAs), microRNAs (miRNAs), and piwi-interacting RNAs (piRNAs). Guided by the interaction with Argonaute proteins, these small RNAs can mediate the degradation or the inhibition of translation of a specific mRNA, making it possible to fine-tune gene expression. In 2018, the US Food and Drug Administration approved Patisiran, the first ever RNAi therapy licensed for clinical use. Patisiran is a formulation of lipid nanoparticles that can be intravenously administered to deliver siRNAs designed to suppress the production of transthyretin, which aggregates into amyloid fibrils that cause nerve damage in patients with hereditary transthyretin amyloidosis.

57Neurodegenerative diseases resulting from a single gene mutation that causes gain-of-function or accumulation of a mutant protein are potential candidates for RNAi. Unfortunately, RNA molecules do not cross the BBB, thus requiring the use of viral or nonviral vectors for CNS delivery. This may result in widespread changes in expression levels in unrelated genes due to nonspecific degradation of nontarget mRNAs and saturation of endogenous silencing pathways.

58For example, RNAi has been investigated in HD, an autosomal-dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene. A potential therapeutic strategy for HD is to reduce mutant HTT expression by using shRNA or miRNA molecules against HTT mRNA. Using RNAi against HTT mRNA does not imply the down-regulation of only the mutated protein, but also of the wild-type protein that plays an important role in neuronal survival. To reduce off-target effects, a series of bioinformatic programs have been developed to predict the hypothetical target mRNAs for each specific miRNA. These programs take into account target complementarity, evolutionary conservation among species, and the thermodynamic stability of the heteroduplex formed by the interaction between miRNAs and mRNAs. Several studies have shown a significant reduction in HTT mRNA together with improved motor function in mouse models of HD upon brain delivery of AAV vectors encoding for shRNA designed to target HTT mRNA. However, evidence of side effects prompted new studies using artificial miRNAs for gene silencing. This approach improved the therapeutic effect in the absence of any detectable detrimental effect up to 9 months after treatment, and has been employed in many subsequent preclinical studies not only on HD but also on superoxide dismutase 1-linked amyotrophic lateral sclerosis.

59New promising tools acting at a post-transcriptional level are short antisense oligonucleotides (ASO, Figure 6 ) with RNA/DNA-based structures that can sequence-specifically hybridize RNA, turning it into a target for RNase H-mediated degradation. The main advantages of ASOs are a higher affinity to target compared with small RNAs, which results in decreased or null off-target toxicity, and the ability to cross the cell membrane to bind RNAs in the cytoplasm or even in the nucleus. ASOs have been intensively tested in human neurodegenerative disorders. For example, ASOs that selectively decrease human tau mRNA have been shown to reduce tau protein deposition and neuronal loss in a mouse model of AD. Moreover, ASOs developed for targeting the mutated form of HTT (mHTT) are currently in clinical development for HD. Initial results with a non-allele specific ASO indicate absence of toxicity and reduced levels of mHTT. Clinical trials with allele-specific ASOs for mHTT are also ongoing.

Conclusions

60The rapid progress of viral and nonviral vector systems has increased the probability of success of CNS gene therapy as an alternative to existing pharmacological treatments. However, all the delivery systems developed thus far have advantages and disadvantages and, therefore, the search for an ideal one continues. A lesson learned from the research performed to date is that delivery tools do not necessarily adapt to all applications, but should be chosen according to the specific situation and need. Understanding the rules of transcriptional and post-transcriptional gene regulation will allow to improve our techniques. In addition, optogenetic and chemogenetic approaches can provide a precise temporal and spatial regulation of gene expression, and the recent introduction of genome-editing technologies allows the direct manipulation of the genome. Therefore, even if more work will be needed to overcome the remaining hurdles, gene therapy now holds a strong promise to become a safe and effective option for CNS diseases in the not too distant future.

Author Contributions

61SI, GV, and MSi wrote the largest part of the article. MSo wrote the chapter on amplicons, and SZ wrote the chapter on viral vectors.

Funding

62This work was supported by grants from the European Community (FP7-PEOPLE-2011-IAPP project 285827 [EPIXCHANGE] and FP7-HEALTH project 602102 [EPITARGET]).

Conflict of Interest Statement

63The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 248

1.
Adams D. Gonzalez-Duarte A. O’Riordan W. D. Yang C. C. Ueda M. Kristen A. V. (2018 ). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379 (1), 11–21.
Not in our library10.1056/nejmoa1716153
2.
Agha-Mohammadi S. O’Malley M. Etemad A. Wang Z. Xiao X. Lotze M. T. (2004 ). Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J. Gene. Med. 6 (7), 817–828.
Not in our library10.1002/jgm.566
3.
Ahmad H. I. Ahmad M. J. Asif A. R. Adnan M. Iqbal M. K. Mehmood K. (2018 ). A review of CRISPR-based genome editing: survival, evolution and challenges. Curr. Issues Mol. Biol. 28, 47–68.
Not in our library10.21775/cimb.028.047
4.
Aiken C. (1997 ). Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71 (8), 5871–5877.
Not in our library10.1128/jvi.71.8.5871-5877.1997
5.
Alexander G. M. Rogan S. C. Abbas A. I. Armbruster B. N. Pei Y. Allen J. A. (2009 ). Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63 (1), 27–39.
Not in our library10.1016/j.neuron.2009.06.014
6.
Armbruster B. N. Li X. Pausch M. H. Herlitze S. Roth B. L. (2007 ). Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. U. S. A. 104 (12), 5163–5168.
Not in our library10.1073/pnas.0700293104
7.
Artusi S. Miyagawa Y. Goins W. F. Cohen J. B. Glorioso J. C. (2018 ). Herpes simplex virus vectors for gene transfer to the central nervous system. Diseases 6 (3), E74.
Not in our library10.3390/diseases6030074
8.
Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain · 2013
No notice
9.
Azzouz M. Martin-Rendon E. Barber R. D. Mitrophanous K. A. Carter E. E. Rohll J. B. (2002 ). Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease. J. Neurosci. 22 (23), 10302–10312.
Not in our library10.1523/jneurosci.22-23-10302.2002
10.
Badawy R. A. B. Harvey A. S. MacDonell R. A. L. (2009 ). Cortical hyperexcitability and epileptogenesis: understanding the mechanisms of epilepsy—Part 2. J. Clin. Neurosci. 16 (4), 485–500.
Not in our library10.1016/j.jocn.2008.10.001
11.
Bayle J. H. Grimley J. S. Stankunas K. Gestwicki J. E. Wandless T. J. Crabtree G. R. (2006 ). Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem. Biol. 13 (1), 99–107.
Not in our library10.1016/j.chembiol.2005.10.017
12.
Bell A. C. West A. G. Felsenfeld G. (1999 ). The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98 (3), 387–396.
Not in our library10.1016/s0092-8674(00)81967-4
13.
Bell C. L. Vandenberghe L. H. Bell P. Limberis M. P. Gao G. P. Van Vliet K. (2011 ). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin Invest. 121 (6), 2427–2435.
Not in our library10.1172/jci57367
14.
Bemelmans A. P. Horellou P. Pradier L. Brunet I. Colin P. Mallet J. (1999 ). Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10 (18), 2987–2997.
Not in our library10.1089/10430349950016393
15.
Berges B. K. Wolfe J. H. Fraser N. W. (2007 ). Transduction of brain by herpes simplex virus vectors. Mol. Ther. 15 (1), 20–29.
Not in our library10.1038/sj.mt.6300018
16.
Berns K. I. Giraud C. (1996 ). Biology of adeno-associated virus. Curr. Top Microbiol. Immunol. 218, 1–23.
Not in our library10.1007/978-3-642-80207-2_1
17.
Bishop A. C. Shah K. Liu Y. Witucki L. Kung C. Y. Shokat K. M. (1998 ). Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol. 8 (5), 257–266.
Not in our library10.1016/s0960-9822(98)70198-8
18.
Bloom D. C. Giordani N. V. Kwiatkowski D. L. (2010 ). Epigenetic regulation of latent HSV-1 gene expression. Biochim. Biophys. Acta 1799 (3-4), 246–256.
Not in our library10.1016/j.bbagrm.2009.12.001
19.
Borel F. Gernoux G. Sun H. Stock R. Blackwood M. Brown R. H. Jr. (2018 ). Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 10 (465), eaau6414.
Not in our library10.1126/scitranslmed.aau6414
20.
Bouard D. Alazard-Dany D. Cosset F. L. (2009 ). Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 157 (2), 153–165.
Not in our library10.1038/bjp.2008.349
21.
Boudreau R. L. McBride J. L. Martins I. Shen S. Xing Y. Carter B. J. (2009 ). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol. Ther. 17 (6), 1053–1063.
Not in our library10.1038/mt.2009.17
22.
Systemic gene delivery to the central nervous system using Adeno-associated virus · 2014
Not checked
23.
Burger C. Gorbatyuk O. S. Velardo M. J. Peden C. S. Williams P. Zolotukhin S. (2004 ). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2), 302–317.
Not in our library10.1016/j.ymthe.2004.05.024
24.
Campos S. K. Barry M. A. (2007 ). Current advances and future challenges in Adenoviral vector biology and targeting. Curr. Gene. Ther. 7 (3), 189–204.
Not in our library10.2174/156652307780859062
25.
Carter M. Shieh J. (2015 ). Guide to research techniques in neuroscience. 2nd. edition Cambridge, MA: Academic Press.
Not in our library
26.
Stable transduction of quiescent CD34+CD38− human hematopoietic cells by HIV-1-based lentiviral vectors · 1999
Not checked
27.
Chan K. Y. Jang M. J. Yoo B. B. Greenbaum A. Ravi N. Wu W. L. (2017 ). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20 (8), 1172–1179.
Not in our library10.1038/nn.4593
28.
Chang S. Y. Lee C. N. Lin P. H. Huang H. H. Chang L. Y. Ko W. (2008 ). A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. J. Med. Virol. 80 (1), 102–112.
Not in our library10.1002/jmv.21045
29.
Chen S. S. Yang C. Hao F. Li C. Lu T. Zhao L. R. (2014 ). Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism. Exp. Neurol. 261, 87–96.
Not in our library10.1016/j.expneurol.2014.06.022
30.
Chen Y. H. Chang M. Davidson B. L. (2009 ). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15 (10), 1215–1218.
Not in our library10.1038/nm.2025
31.
Progresses towards safe and efficient gene therapy vectors · 2015
No notice
32.
Choi-Lundberg D. L. Lin Q. Schallert T. Crippens D. Davidson B. L. Chang Y. N. (1998 ). Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154 (2), 261–275.
Not in our library10.1006/exnr.1998.6887
33.
Choudhury S. R. Harris A. F. Cabral D. J. Keeler A. M. Sapp E. Ferreira J. S. (2016 ). Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol. Ther. 24 (4), 726–735.
Not in our library10.1038/mt.2015.231
34.
Chow B. Y. Han X. Dobry A. S. Qian X. Chuong A. S. Li M. (2010 ). High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature 463 (7277), 98–102.
Not in our library10.1038/nature08652
35.
Christ M. Lusky M. Stoeckel F. Dreyer D. Dieterle A. Michou A. I. (1997 ). Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57 (1–3), 19–25.
Not in our library10.1016/s0165-2478(97)00049-7
36.
Christine C. W. Starr P. A. Larson P. S. Eberling J. L. Jagust W. J. Hawkins R. A. (2009 ). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 (20), 1662–1669.
Not in our library10.1212/wnl.0b013e3181c29356
37.
Chung J. H. Whiteley M. Felsenfeld G. (1993 ). A 5’ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74 (3), 505–514.
Not in our library10.1016/0092-8674(93)80052-g
38.
Coelho T. Adams D. Silva A. Lozeron P. Hawkins P. N. Mant T. (2013 ). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (9), 819–829.
Not in our library10.1056/nejmoa1208760
39.
Cohen M. S. Zhang C. Shokat K. M. Taunton J. (2005 ). Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308 (5726), 1318–1321.
Not in our library10.1126/science1108367
40.
Cooray S. Howe S. J. Thrasher A. J. (2012 ). Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol 507, 29–57.
Not in our library10.1016/b978-0-12-386509-0.00003-x
41.
Controlling signaling with a specifically designed Gi-coupled receptor · 1998
Not checked
42.
Crick F. H. (1979 ). Thinking about the brain. Sci. Am. 241 (3), 219–232.
Not in our library10.1038/scientificamerican0979-219
43.
Cucchiarini M. (2016 ). Human gene therapy: novel approaches to improve the current gene delivery systems. Discov. Med. 21 (118), 495–506.
Not in our library
44.
Cuchet D. Potel C. Thomas J. Epstein A. L. (2007 ). HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin. Biol. Ther. 7 (7), 975–995.
Not in our library10.1517/14712598.7.7.975
45.
Dar A. C. Das T. K. Shokat K. M. Cagan R. L. (2012 ). Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486 (7401), 80–U101.
Not in our library10.1038/nature11127
46.
Das A. T. Zhou X. Vink M. Klaver B. Verhoef K. Marzio G. (2004 ). Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J. Biol. Chem. 279 (18), 18776–18782.
Not in our library10.1074/jbc.m313895200
47.
Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system · 2000
Not checked
48.
Altering neuronal excitability to preserve network connectivity in a computational model of Alzheimer's disease. · 2017
Not checked
49.
Deisseroth K. (2011 ). Optogenetics. Nat. Methods 8 (1), 26–29.
Not in our library10.1038/nmeth.f.324
50.
Deisseroth K. (2015 ). Optogenetics: 10 years of microbial opsins in neuroscience. Nat. Neurosci. 18 (9), 1213–1225.
Not in our library10.1038/nn.4091
51.
Deverman B. E. Pravdo P. L. Simpson B. P. Kumar S. R. Chan K. Y. Banerjee A. (2016 ). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34 (2), 204–209.
Not in our library10.1038/nbt.3440
52.
DeVos S. L. Miller R. L. Schoch K. M. Holmes B. B. Kebodeaux C. S. Wegener A. J. (2017 ). Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9 (374), eaa90481.
Not in our library10.1126/scitranslmed.aag0481
53.
Dobbelstein M. (2004 ). Replicating adenoviruses in cancer therapy. Curr. Top Microbiol. Immunol. 273, 291–334.
Not in our library10.1007/978-3-662-05599-1_9
54.
Drouet V. Perrin V. Hassig R. Dufour N. Auregan G. Alves S. (2009 ). Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 65 (3), 276–285.
Not in our library10.1002/ana.21569
55.
Duan D. (2016 ). Systemic delivery of adeno-associated viral vectors. Curr. Opin. Virol. 21, 16–25.
Not in our library10.1016/j.coviro.2016.07.006
56.
Duan D. Sharma P. Yang J. Yue Y. Dudus L. Zhang Y. (1998 ). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72 (11), 8568–8577.
Not in our library10.1128/jvi.72.11.8568-8577.1998
57.
Duan D. Yue Y. Engelhardt J. F. (2001 ). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4 (4), 383–391.
Not in our library10.1006/mthe.2001.0456
58.
Dufes C. Uchegbu I. F. Schatzlein A. G. (2005 ). Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57 (15), 2177–2202.
Not in our library10.1016/j.addr.2005.09.017
59.
Dutta S. Basak B. Bhunia B. Chakraborty S. Dey A. (2014 ). Kinetics of rapamycin production by Streptomyces hygroscopicus MTCC 4003. 3 Biotech 4 (5), 523–531.
Not in our library10.1007/s13205-013-0189-2
60.
Eberling J. L. Jagust W. J. Christine C. W. Starr P. Larson P. Bankiewicz K. S. (2008 ). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 (21), 1980–1983.
Not in our library10.1212/01.wnl.0000312381.29287.ff
61.
Ebert A. D. Chen F. He X. Cryns V. L. Bohn M. C. (2005 ). A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp. Neurol. 191 Suppl 1, S80–94.
Not in our library10.1016/j.expneurol.2004.08.024
62.
Emery D. W. (2011 ). The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum. Gene Ther. 22 (6), 761–774.
Not in our library10.1089/hum.2010.233
63.
Epstein A. L. (2009 a). HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties - A review. Mem. Inst. Oswaldo Cruz 104 (3), 399–410.
Not in our library10.1590/s0074-02762009000300002
64.
Epstein A. L. (2009 b). Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 16 (6), 709–715.
Not in our library10.1038/gt.2009.42
65.
Falcicchia C. Trempat P. Binaschi A. Perrier-Biollay C. Roncon P. Soukupova M. (2016 ). Silencing status epilepticus-induced BDNF expression with herpes simplex virus type-1 based amplicon vectors. PLoS One 11 (3), e0150995.
Not in our library10.1371/journal.pone.0150995
66.
Foust K. D. Salazar D. L. Likhite S. Ferraiuolo L. Ditsworth D. Ilieva H. (2013 ). Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 21 (12), 2148–2159.
Not in our library10.1038/mt.2013.211
67.
Gaj T. Sirk S. J. Shui S. L. Liu J. (2016 ). Genome-editing technologies: principles and applications. Cold Spring Harb. Perspect. Biol. 8 (12), 9023754.
Not in our library10.1101/cshperspect.a023754
68.
Gardlik R. Palffy R. Hodosy J. Lukacs J. Turna J. Celec P. (2005 ). Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11 (4), RA110–121.
Not in our library
69.
Gaszner M. Felsenfeld G. (2006 ). Insulators: exploiting transcriptional and epigenetic mechanisms. Nat. Rev. Genet. 7 (9), 703–713.
Not in our library10.1038/nrg1925
70.
Geary R. S. Norris D. Yu R. Bennett C. F. (2015 ). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51.
Not in our library10.1016/j.addr.2015.01.008
71.
Georgievska B. Jakobsson J. Persson E. Ericson C. Kirik D. Lundberg C. (2004 ). Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum. Gene Ther. 15 (10), 934–944.
Not in our library10.1089/hum.2004.15.934
72.
Ghosh A. Yue Y. Lai Y. Duan D. (2008 ). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16 (1), 124–130.
Not in our library10.1038/sj.mt.6300322
73.
Non-Coding RNAs: Multi-Tasking Molecules in the Cell · 2013
No notice
74.
Gossen M. Freundlieb S. Bender G. Muller G. Hillen W. Bujard H. (1995 ). Transcriptional activation by tetracyclines in mammalian cells. Science 268 (5218), 1766–1769.
Not in our library10.1126/science.7792603
75.
Goverdhana S. Puntel M. Xiong W. Zirger J. M. Barcia C. Curtin J. F. (2005 ). Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12 (2), 189–211.
Not in our library10.1016/j.ymthe.2005.03.022
76.
Grimm D. Lee J. S. Wang L. Desai T. Akache B. Storm T. A. (2008 ). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (12), 5887–5911.
Not in our library10.1128/jvi.00254-08
77.
Grimm D. Streetz K. L. Jopling C. L. Storm T. A. Pandey K. Davis C. R. (2006 ). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441 (7092), 537–541.
Not in our library10.1038/nature04791
78.
Gruh I. Wunderlich S. Winkler M. Schwanke K. Heinke J. Blomer U. (2008 ). Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J. Gene. Med. 10 (1), 21–32.
Not in our library10.1002/jgm.1122
79.
Gunaydin L. A. Yizhar O. Berndt A. Sohal V. S. Deisseroth K. Hegemann P. (2010 ). Ultrafast optogenetic control. Nat. Neurosci. 13 (3), 387–392.
Not in our library10.1038/nn.2495
80.
Hadaczek P. Beyer J. Kells A. Narrow W. Bowers W. Federoff H. J. (2011 ). Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One 6 (11), e27728.
Not in our library10.1371/journal.pone.0027728
81.
Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection · 2017
No notice
82.
Han F. Miyagawa Y. Verlengia G. Ingusci S. Soukupova M. Simonato M. (2018 ). Cellular antisilencing elements support transgene expression from herpes simplex virus vectors in the absence of immediate early gene expression. J. Virol. 92 (17), e00536–18.
Not in our library10.1128/jvi.00536-18
83.
Harper S. Q. Staber P. D. He X. Eliason S. L. Martins I. H. Mao Q. (2005 ). RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (16), 5820–5825.
Not in our library10.1073/pnas.0501507102
84.
Hartikka J. Sawdey M. Cornefert-Jensen F. Margalith M. Barnhart K. Nolasco M. (1996 ). An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 7 (10), 1205–1217.
Not in our library10.1089/hum.1996.7.10-1205
85.
Hock J. Meister G. (2008 ). The Argonaute protein family. Genome Biol. 9 (2), 210.
Not in our library10.1186/gb-2008-9-2-210
86.
Howell D. P. Krieser R. J. Eastman A. Barry M. A. (2003 ). Deoxyribonuclease II is a lysosomal barrier to transfection. Mol. Ther. 8 (6), 957–963.
Not in our library10.1016/j.ymthe.2003.09.011
87.
Huang R. Q. Qu Y. H. Ke W. L. Zhu J. H. Pei Y. Y. Jiang C. (2007 ). Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 21 (4), 1117–1125.
Not in our library10.1096/fj.06-7380com
88.
Ikeda K. Wakimoto H. Ichikawa T. Jhung S. Hochberg F. H. Louis D. N. (2000 ). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74 (10), 4765–4775.
Not in our library10.1128/jvi.74.10.4765-4775.2000
89.
Jackson A. L. Bartz S. R. Schelter J. Kobayashi S. V. Burchard J. Mao M., et al. (2003 ). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21 (6), 635–637.
Not in our library10.1038/nbt831
90.
Jarraya B. Boulet S. Ralph G. S. Jan C. Bonvento G. Azzouz M. (2009 ). Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med. 1 (2), 2ra4.
Not in our library10.1126/scitranslmed.3000130
91.
Jayant R. D. Sosa D. Kaushik A. Atluri V. Vashist A. Tomitaka A. (2016 ). Current status of non-viral gene therapy for CNS disorders. Expert Opin. Drug Deliv. 13 (10), 1433–1445.
Not in our library10.1080/17425247.2016.1188802
92.
Kaludov N. Brown K. E. Walters R. W. Zabner J. Chiorini J. A. (2001 ). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75 (15), 6884–6893.
Not in our library10.1128/jvi.75.15.6884-6893.2001
93.
Kang C. B. Hong Y. Dhe-Paganon S. Yoon H. S. (2008 ). FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16 (4), 318–325.
Not in our library10.1159/000123041
94.
Kaplitt M. G. Feigin A. Tang C. Fitzsimons H. L. Mattis P. Lawlor P. A. (2007 ). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369 (9579), 2097–2105.
Not in our library10.1016/s0140-6736(07)60982-9
95.
Katsouri L. Lim Y. M. Blondrath K. Eleftheriadou I. Lombardero L. Birch A. M. (2016 ). PPARgamma-coactivator-1alpha gene transfer reduces neuronal loss and amyloid-beta generation by reducing beta-secretase in an Alzheimer’s disease model. Proc. Natl. Acad. Sci. U. S. A. 113 (43), 12292–12297.
Not in our library10.1073/pnas.1606171113
96.
Chemical–genetic attenuation of focal neocortical seizures · 2014
No notice
97.
Kay M. A. Liu D. Hoogerbrugge P. M. (1997 ). Gene therapy. Proc. Natl. Acad. Sci. U. S. A. 94 (24), 12744–12746.
Not in our library10.1073/pnas.94.24.12744
98.
Khare R. Chen C. Y. Weaver E. A. Barry M. A. (2011 ). Advances and future challenges in adenoviral vector pharmacology and targeting. Curr. Gene. Ther. 11 (4), 241–258.
Not in our library10.2174/156652311796150363
99.
Klug B. Celis P. Carr M. Reinhardt J. (2012 ). Regulatory structures for gene therapy medicinal products in the European Union. Methods Enzymol 507, 337–354.
Not in our library10.1016/b978-0-12-386509-0.00017-x
100.
Knorr V. Allmendinger L. Walker G. F. Paintner F. F. Wagner E. (2007 ). An acetal-based PEGylation reagent for pH-Sensitive shielding of DNA polyplexes. Bioconjug. Chem. 18 (4), 1218–1225.
Not in our library10.1021/bc060327a
101.
Kodippili K. Hakim C. H. Pan X. Yang H. T. Yue Y. Zhang Y. (2018 ). Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum. Gene Ther. 29 (3), 299–311.
Not in our library10.1089/hum.2017.095
102.
A brain microvasculature endothelial cell‐specific viral vector with the potential to treat neurovascular and neurological diseases · 2016
No notice
103.
Krashes M. J. Shah B. P. Madara J. C. Olson D. P. Strochlic D. E. Garfield A. S. (2014 ). An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. Nature 507 (7491), 238–+.
Not in our library10.1038/nature12956
104.
Kravitz A. V. Freeze B. S. Parker P. R. L. Kay K. Thwin M. T. Deisseroth K. (2010 ). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466 (7306), U622–U627.
Not in our library10.1038/nature09159
105.
Kremer B. Goldberg P. Andrew S. E. Theilmann J. Telenius H. Zeisler J. (1994 ). A worldwide study of the Huntington’s disease mutation. N. Engl. J. Med. 330 (20), 1401–1406.
Not in our library10.1056/nejm199405193302001
106.
Krisky D. M. Wolfe D. Goins W. F. Marconi P. C. Ramakrishnan R. Mata M. (1998 ). Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5 (12), 1593–1603.
Not in our library10.1038/sj.gt.3300766
107.
Krook-Magnuson E. Armstrong C. Oijala M. Soltesz I. (2013 ). On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun. 4, 1376.
Not in our library10.1038/ncomms2376
108.
Kugler S. Kilic E. Bahr M. (2003 ). Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 10 (4), 337–347.
Not in our library10.1038/sj.gt.3301905
109.
Kugler S. Meyn L. Holzmuller H. Gerhardt E. Isenmann S. Schulz J. B. (2001 ). Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol. Cell Neurosci. 17 (1), 78–96.
Not in our library10.1006/mcne.2000.0929
110.
Lachmann R. (2004 ). Herpes simplex virus-based vectors. Int. J. Exp. Pathol. 85 (4), 177–190.
Not in our library10.1111/j.0959-9673.2004.00383.x
111.
Lachmann R. H. Brown C. Efstathiou S. (1996 ). A murine RNA polymerase I promoter inserted into the herpes simplex virus type 1 genome is functional during lytic, but not latent, infection. J. Gen. Virol. 77 (Pt 10), 2575–2582.
Not in our library10.1099/0022-1317-77-10-2575
112.
Le Guiner C. Stieger K. Toromanoff A. Guilbaud M. Mendes-Madeira A. Devaux M. (2014 ). Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates. PLoS One 9 (9), e102538.
Not in our library10.1371/journal.pone.0102538
113.
Lee C. S. Bishop E. S. Zhang R. Yu X. Farina E. M. Yan S. (2017 ). Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 4 (2), 43–63.
Not in our library10.1016/j.gendis.2017.04.001
114.
Lee Y. Messing A. Su M. Brenner M. (2008 ). GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56 (5), 481–493.
Not in our library10.1002/glia.20622
115.
Lee Y. B. Cosgrave A. S. Glover C. P. Bienemann A. Heywood D. Hobson R. J. (2005 ). Increased utility in the CNS of a powerful neuron-specific tetracycline-regulatable adenoviral system developed using a post-transcriptional enhancer. J. Gene Med. 7 (5), 576–583.
Not in our library10.1002/jgm.694
116.
Lenman A. Liaci A. M. Liu Y. Frangsmyr L. Frank M. Blaum B. S. (2018 ). Polysialic acid is a cellular receptor for human adenovirus 52. Proc. Natl. Acad. Sci. U. S. A. 115 (18), E4264–E4273.
Not in our library10.1073/pnas.1716900115
117.
Li S. D. Huang L. (2006 ). Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther. 13 (18), 1313–1319.
Not in our library10.1038/sj.gt.3302838
118.
Li X. Heyer W. D. (2008 ). Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18 (1), 99–113.
Not in our library10.1038/cr.2008.1
119.
Lieber M. R. (2010 ). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181–211.
Not in our library10.1146/annurev.biochem.052308.093131
120.
Liu Y. Jacques S. L. Azimipour M. Rogers J. D. Pashaie R. Eliceiri K. W. (2015 ). OptogenSIM: a 3D Monte Carlo simulation platform for light delivery design in optogenetics. Biomed. Opt. Express 6 (12), 4859–4870.
Not in our library10.1364/boe.6.004859
121.
Lombardo A. Genovese P. Beausejour C. M. Colleoni S. Lee Y. L. Kim K. A. (2007 ). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25 (11), 1298–1306.
Not in our library10.1038/nbt1353
122.
Lowenstein P. R. Castro M. G. (2002 ). Progress and challenges in viral vector-mediated gene transfer to the brain. Curr. Opin. Mol. Ther. 4 (4), 359–371.
Not in our library
123.
Lowenstein P. R. Castro M. G. (2003 ). Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther. 10 (11), 946–954.
Not in our library10.1038/sj.gt.3302048
124.
Lowenstein P. R. Castro M. G. (2004 ). Recent advances in the pharmacology of neurological gene therapy. Curr. Opin. Pharmacol. 4 (1), 91–97.
Not in our library10.1016/j.coph.2003.10.005
125.
Maddalena A. Tornabene P. Tiberi P. Minopoli R. Manfredi A. Mutarelli M. (2018 ). Triple vectors expand AAV transfer capacity in the retina. Mol. Ther. 26 (2), 524–541.
Not in our library10.1016/j.ymthe.2017.11.019
126.
Magnus C. J. Lee P. H. Atasoy D. Su H. H. Looger L. L. Sternson S. M. (2011 ). Chemical and genetic engineering of selective ion channel–ligand interactions. Science 333 (6047), 1292–1296.
Not in our library10.1126/science.1206606
127.
Mandel R. J. Manfredsson F. P. Foust K. D. Rising A. Reimsnider S. Nash K. (2006 ). Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol. Ther. 13 (3), 463–483.
Not in our library10.1016/j.ymthe.2005.11.009
128.
Manthorpe M. Cornefert-Jensen F. Hartikka J. Felgner J. Rundell A. Margalith M. (1993 ). Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4 (4), 419–431.
Not in our library10.1089/hum.1993.4.4-419
129.
Mao Y. Wang X. Yan R. Hu W. Li A. Wang S. (2016 ). Single point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivo. BMC Biotechnol. 16, 1.
Not in our library10.1186/s12896-015-0230-0
130.
Marconi P. Simonato M. Zucchini S. Bregola G. Argnani R. Krisky D. (1999 ). Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther. 6 (5), 904–912.
Not in our library10.1038/sj.gt.3300882
131.
Martin-Gallardo A. Montoya-Zavala M. Kelder B. Taylor J. Chen H. Leung F. C. (1988 ). A comparison of bovine growth-hormone gene expression in mouse L cells directed by the Moloney murine-leukemia virus long terminal repeat, simian virus-40 early promoter or cytomegalovirus immediate-early promoter. Gene 70 (1), 51–56.
Not in our library10.1016/0378-1119(88)90103-5
132.
Matsumoto Y. Itaka K. Yamasoba T. Kataoka K. (2009 ). Intranuclear fluorescence resonance energy transfer analysis of plasmid DNA decondensation from nonviral gene carriers. J. Gene. Med. 11 (7), 615–623.
Not in our library10.1002/jgm.1338
133.
Mattick J. S. Makunin I. V. (2006 ). Non-coding RNA. Hum. Mol. Genet. 15 Spec No 1, R17–29.
Not in our library10.1093/hmg/ddl046
134.
Maurice M. Verhoeyen E. Salmon P. Trono D. Russell S. J. Cosset F. L. (2002 ). Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99 (7), 2342–2350.
Not in our library10.1182/blood.v99.7.2342
135.
McLean J. R. Smith G. A. Rocha E. M. Hayes M. A. Beagan J. A. Hallett P. J. (2014 ). Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci. Lett. 576, 73–78.
Not in our library10.1016/j.neulet.2014.05.044
136.
Mendell J. R. Al-Zaidy S. Shell R. Arnold W. D. Rodino-Klapac L. R. Prior T. W. (2017 ). Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377 (18), 1713–1722.
Not in our library10.1056/nejmoa1706198
137.
Clinical use of lentiviral vectors · 2018
No notice
138.
Miniarikova J. Zanella I. Huseinovic A. van der Zon T. Hanemaaijer E. Martier R. (2016 ). Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington’s disease. Mol. Ther. Nucleic Acids 5, e297.
Not in our library10.1038/mtna.2016.7
139.
Mittermeyer G. Christine C. W. Rosenbluth K. H. Baker S. L. Starr P. Larson P. (2012 ). Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum. Gene Ther. 23 (4), 377–381.
Not in our library10.1089/hum.2011.220
140.
Miyagawa Y. Marino P. Verlengia G. Uchida H. Goins W. F. Yokota S. (2015 ). Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 112 (13), E1632–1641.
Not in our library10.1073/pnas.1423556112
141.
Miyagawa Y. Verlengia G. Reinhart B. Han F. Uchida H. Zucchini S. (2017 ). Deletion of the virion host shut-off gene enhances neuronal-selective transgene expression from an HSV vector lacking functional IE genes. Mol. Ther. Methods Clin. Dev. 6, 79–90.
Not in our library10.1016/j.omtm.2017.06.001
142.
Morris S. J. Farley D. C. Leppard K. N. (2010 ). Generation of cell lines to complement adenovirus vectors using recombination-mediated cassette exchange. BMC Biotechnol. 10, 92.
Not in our library10.1186/1472-6750-10-92
143.
Musatov S. Roberts J. Pfaff D. Kaplitt M. (2002 ). A cis-acting element that directs circular adeno-associated virus replication and packaging. J. Virol. 76 (24), 12792–12802.
Not in our library10.1128/jvi.76.24.12792-12802.2002
144.
Nagel G. Szellas T. Huhn W. Kateriya S. Adeishvili N. Berthold P. (2003 ). Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc. Natl. Acad. Sci. U. S. A. 100 (24), 13940–13945.
Not in our library10.1073/pnas.1936192100
145.
Naidoo J. Young D. (2012 ). Gene regulation systems for gene therapy applications in the central nervous system. Neurol. Res. Int. 2012, 595410.
Not in our library10.1155/2012/595410
146.
Nakai H. Fuess S. Storm T. A. Muramatsu S. Nara Y. Kay M. A. (2005 ). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79 (1), 214–224.
Not in our library10.1128/jvi.79.1.214-224.2005
147.
Nakai H. Iwaki Y. Kay M. A. Couto L. B. (1999 ). Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J. Virol. 73 (7), 5438–5447.
Not in our library10.1128/jvi.73.7.5438-5447.1999
148.
Naso M. F. Tomkowicz B. Perry W. L. 3rd Strohl W. R. (2017 ). Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31 (4), 317–334.
Not in our library10.1007/s40259-017-0234-5
149.
Nau R. Sorgel F. Eiffert H. (2010 ). Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23 (4), 858–883.
Not in our library10.1128/cmr.00007-10
150.
Oellig C. Seliger B. (1990 ). Gene transfer into brain tumor cell lines: reporter gene expression using various cellular and viral promoters. J. Neurosci. Res. 26 (3), 390–396.
Not in our library10.1002/jnr.490260317
151.
Oesterhelt D. Stoeckenius W. (1971 ). Rhodopsin-like protein from the purple membrane of Halobacterium halobium. Nat. New Biol. 233 (39), 149–152.
Not in our library10.1038/newbio233149a0
152.
Ogris M. Brunner S. Schuller S. Kircheis R. Wagner E. (1999 ). PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6 (4), 595–605.
Not in our library10.1038/sj.gt.3300900
153.
Palella T. D. Silverman L. J. Schroll C. T. Homa F. L. Levine M. Kelley W. N. (1988 ). Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells. Mol. Cell Biol. 8 (1), 457–460.
Not in our library10.1128/mcb.8.1.457
154.
Palfi S. Gurruchaga J. M. Lepetit H. Howard K. Ralph G. S. Mason S. (2018 ). Long-term follow-up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson’s disease. Hum. Gene Ther. Clin. Dev. 29 (3), 148–155.
Not in our library10.1089/humc.2018.081
155.
Palfi S. Gurruchaga J. M. Ralph G. S. Lepetit H. Lavisse S. Buttery P. C. (2014 ). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383 (9923), 1138–1146.
Not in our library10.1016/s0140-6736(13)61939-x
156.
Pasleau F. Tocci M. J. Leung F. Kopchick J. J. (1985 ). Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate-early promoter. Gene 38 (1–3), 227–232.
Not in our library10.1016/0378-1119(85)90221-5
157.
Pasquale T. R. Tan J. S. (2005 ). Nonantimicrobial effects of antibacterial agents. Clin. Infect. Dis. 40 (1), 127–135.
Not in our library10.1086/426545
158.
Pechan P. A. Fotaki M. Thompson R. L. Dunn R. Chase M. Chiocca E. A. (1996 ). A novel ‘piggyback’ packaging system for herpes simplex virus amplicon vectors. Hum. Gene Ther. 7 (16), 2003–2013.
Not in our library10.1089/hum.1996.7.16-2003
159.
Peel A. L. Zolotukhin S. Schrimsher G. W. Muzyczka N. Reier P. J. (1997 ). Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4 (1), 16–24.
Not in our library10.1038/sj.gt.3300358
160.
Penaud-Budloo M. Francois A. Clement N. Ayuso E. (2018 ). Pharmacology of recombinant adeno-associated virus production. Mol. Ther. Methods Clin. Dev. 8, 166–180.
Not in our library10.1016/j.omtm.2018.01.002
161.
Perez-Martinez F. C. Guerra J. Posadas I. Cena V. (2011 ). Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm. Res. 28 (8), 1843–1858.
Not in our library10.1007/s11095-010-0364-7
162.
Persengiev S. P. Zhu X. Green M. R. (2004 ). Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10 (1), 12–18.
Not in our library10.1261/rna5160904
163.
Pfister E. L. Chase K. O. Sun H. Kennington L. A. Conroy F. Johnson E. (2017 ). Safe and efficient silencing with a Pol II, but not a Pol lII, promoter expressing an artificial miRNA targeting human Huntingtin. Mol. Ther. Nucleic Acids 7, 324–334.
Not in our library10.1016/j.omtn.2017.04.011
164.
Pfister E. L. DiNardo N. Mondo E. Borel F. Conroy F. Fraser C. (2018 ). Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington’s disease. Hum. Gene Ther. 29 (6), 663–673.
Not in our library10.1089/hum.2017.199
165.
Phillips J. E. Corces V. G. (2009 ). CTCF: master weaver of the genome. Cell 137 (7), 1194–1211.
Not in our library10.1016/j.cell.2009.06.001
166.
Pienaar I. S. Gartside S. E. Sharma P. De Paola V. Gretenkord S. Withers D. (2015 ). Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson’s disease. Mol. Neurodegener. 10, 47.
Not in our library10.1186/s13024-015-0044-5
167.
Piest M. Lin C. Mateos-Timoneda M. A. Lok M. C. Hennink W. E. Feijen J. (2008 ). Novel poly(amido amine)s with bioreducible disulfide linkages in their diamino-units: structure effects and in vitro gene transfer properties. J. Control. Release 132 (3), E12–E13.
Not in our library10.1016/j.jconrel.2008.09.047
168.
Pluta K. Luce M. J. Bao L. Agha-Mohammadi S. Reiser J. (2005 ). Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J. Gene Med. 7 (6), 803–817.
Not in our library10.1002/jgm.712
169.
Potkin K. T. Potkin S. G. (2018 ). New directions in therapeutics for Huntington disease. Future Neurol. 13 (2), 101–121.
Not in our library10.2217/fnl-2017-0035
170.
Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter · 2010
No notice
171.
Raab J. R. Kamakaka R. T. (2010 ). Insulators and promoters: closer than we think. Nat. Rev. Genet. 11 (6), 439–446.
Not in our library10.1038/nrg2765
172.
Rafii M. S. Baumann T. L. Bakay R. A. Ostrove J. M. Siffert J. Fleisher A. S. (2014 ). A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement. 10 (5), 571–581.
Not in our library10.1016/j.jalz.2013.09.004
173.
Non Viral Vectors in Gene Therapy- An Overview · 2015
Not checked
174.
Rasmussen M. Kong L. Zhang G. R. Liu M. Wang X. Szabo G. (2007 ). Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter. Brain Res. 1144, 19–32.
Not in our library10.1016/j.brainres.2007.01.125
175.
Rein D. T. Breidenbach M. Curiel D. T. (2006 ). Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2 (1), 137–143.
Not in our library10.2217/14796694.2.1.137
176.
Reiner A. Dragatsis I. Zeitlin S. Goldowitz D. (2003 ). Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 28 (3), 259–276.
Not in our library10.1385/mn:28:3:259
177.
Reynolds A. Leake D. Boese Q. Scaringe S. Marshall W. S. Khvorova A. (2004 ). Rational siRNA design for RNA interference. Nat. Biotechnol. 22 (3), 326–330.
Not in our library10.1038/nbt936
178.
Ritter T. Lehmann M. Volk H. D. (2002 ). Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 16 (1), 3–10.
Not in our library10.2165/00063030-200216010-00001
179.
Rivella S. Callegari J. A. May C. Tan C. W. Sadelain M. (2000 ). The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. 74 (10), 4679–4687.
Not in our library10.1128/jvi.74.10.4679-4687.2000
180.
Rivera V. M. Clackson T. Natesan S. Pollock R. Amara J. F. Keenan T. (1996 ). A humanized system for pharmacologic control of gene expression. Nat. Med. 2 (9), 1028–1032.
Not in our library10.1038/nm0996-1028
181.
Rodriguez-Lebron E. Denovan-Wright E. M. Nash K. Lewin A. S. Mandel R. J. (2005 ). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol. Ther. 12 (4), 618–633.
Not in our library10.1016/j.ymthe.2005.05.006
182.
Rosario A. M. Cruz P. E. Ceballos-Diaz C. Strickland M. R. Siemienski Z. Pardo M. (2016 ). Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev. 3, 16026.
Not in our library10.1038/mtm.2016.26
183.
Sakuma T. Barry M. A. Ikeda Y. (2012 ). Lentiviral vectors: basic to translational. Biochem. J. 443 (3), 603–618.
Not in our library10.1042/bj20120146
184.
Samaniego L. A. Wu N. DeLuca N. A. (1997 ). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71 (6), 4614–4625.
Not in our library10.1128/jvi.71.6.4614-4625.1997
185.
Sanftner L. M. Rivera V. M. Suzuki B. M. Feng L. Berk L. Zhou S. (2006 ). Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol. Ther. 13 (1), 167–174.
Not in our library10.1016/j.ymthe.2005.06.480
186.
Scacheri P. C. Rozenblatt-Rosen O. Caplen N. J. Wolfsberg T. G. Umayam L. Lee J. C. (2004 ). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 101 (7), 1892–1897.
Not in our library10.1073/pnas.0308698100
187.
Seeger-Armbruster S. Bosch-Bouju C. Little S. T. Smither R. A. Hughes S. M. Hyland B. I. (2015 ). Patterned, but not tonic, optogenetic stimulation in motor thalamus improves reaching in acute drug-induced Parkinsonian rats. J. Neurosci. 35 (3), 1211–1216.
Not in our library10.1523/jneurosci.3277-14.2015
188.
Sharma A. Tandon M. Bangari D. S. Mittal S. K. (2009 ). Adenoviral vector-based strategies for cancer therapy. Curr. Drug Ther. 4 (2), 117–138.
Not in our library10.2174/157488509788185123
189.
Shen S. Bryant K. D. Brown S. M. Randell S. H. Asokan A. (2011 ). Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286 (15), 13532–13540.
Not in our library10.1074/jbc.m110.210922
190.
Shepard A. A. DeLuca N. A. (1991 ). A second-site revertant of a defective herpes simplex virus ICP4 protein with restored regulatory activities and impaired DNA-binding properties. J. Virol. 65 (2), 787–795.
Not in our library10.1128/jvi.65.2.787-795.1991
191.
Shillitoe E. J. (2009 ). Gene therapy: the end of the rainbow? Head Neck Oncol. 1, 7.
Not in our library10.1186/1758-3284-1-7
192.
Simonato M. (2014 ). Gene therapy for epilepsy. Epilepsy Behav. 38, 125–130.
Not in our library10.1016/j.yebeh.2013.09.013
193.
Simonato M. Bennett J. Boulis N. M. Castro M. G. Fink D. J. Goins W. F. (2013 ). Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9 (5), 277–291.
Not in our library10.1038/nrneurol.2013.56
194.
Simonato M. Manservigi R. Marconi P. Glorioso J. (2000 ). Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends Neurosci. 23 (5), 183–190.
Not in our library10.1016/s0166-2236(99)01539-8
195.
Sinclair A. M. Agrawal Y. P. Elbar E. Agrawal R. Ho A. D. Levine F. (1997 ). Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+ CD38- hematopoietic progenitor cells. Gene Ther. 4 (9), 918–927.
Not in our library10.1038/sj.gt.3300479
196.
Smith-Arica J. R. Morelli A. E. Larregina A. T. Smith J. Lowenstein P. R. Castro M. G. (2000 ). Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Mol. Ther. 2 (6), 579–587.
Not in our library10.1006/mthe.2000.0215
197.
Souweidane M. M. Fraser J. F. Arkin L. M. Sondhi D. Hackett N. R. Kaminsky S. M. (2010 ). Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J. Neurosurg. Pediatr. 6 (2), 115–122.
Not in our library10.3171/2010.4.peds09507
198.
Sternson S. M. Roth B. L. (2014 ). Chemogenetic tools to interrogate brain functions. Annu. Rev. Neurosci. 37, 387–407.
Not in our library10.1146/annurev-neuro-071013-014048
199.
Strader C. D. Gaffney T. Sugg E. E. Candelore M. R. Keys R. Patchett A. A. (1991 ). Allele-specific activation of genetically engineered receptors. J. Biol. Chem. 266 (1), 5–8.
Not in our library
200.
Studahl M. Cinque P. Bergström T., (2017 ). Herpes simplex viruses. 1st Edition Boca Raton, FL: CRC Press p. 440.
Not in our library10.1201/9780203711828
201.
Sutton R. E. Reitsma M. J. Uchida N. Brown P. O. (1999 ). Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J. Virol. 73 (5), 3649–3660.
Not in our library10.1128/jvi.73.5.3649-3660.1999
202.
Suzuki M. Kasai K. Saeki Y. (2006 ). Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J. Virol. 80 (7), 3293–3300.
Not in our library10.1128/jvi.80.7.3293-3300.2006
203.
Tabrizi S. J. Leavitt B. R. Landwehrmeyer G. B. Wild E. J. Saft C. Barker R. A. (2019 ). Targeting Huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380 (24), 2307–2316.
Not in our library10.1056/nejmoa1900907
204.
Tardieu M. Zerah M. Husson B. de Bournonville S. Deiva K. Adamsbaum C. (2014 ). Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 25 (6), 506–516.
Not in our library10.1089/hum.2013.238
205.
Teissier A. Chemiakine A. Inbar B. Bagchi S. Ray R. S. Palmiter R. D. (2015 ). Activity of raphe serotonergic neurons controls emotional behaviors. Cell Rep. 13 (9), 1965–1976.
Not in our library10.1016/j.celrep.2015.10.061
206.
Teschemacher A. G. Wang S. Lonergan T. Duale H. Waki H. Paton J. F. (2005 ). Targeting specific neuronal populations using adeno- and lentiviral vectors: applications for imaging and studies of cell function. Exp. Physiol. 90 (1), 61–69.
Not in our library10.1113/expphysiol.2004.028191
207.
Thomas C. E. Ehrhardt A. Kay M. A. (2003 ). Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4 (5), 346–358.
Not in our library10.1038/nrg1066
208.
Tian X. Wang G. Xu Y. Wang P. Chen S. Yang H. (2009 ). An improved tet-on system for gene expression in neurons delivered by a single lentiviral vector. Hum. Gene Ther. 20 (2), 113–123.
Not in our library10.1089/hum.2008.018
209.
Todo T. (2008 ). “Armed” oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh. Migr. 2 (3), 208–213.
Not in our library10.4161/cam.2.3.6353
210.
Effective delivery of large genes to the retina by dual AAV vectors · 2013
No notice
211.
Urban D. J. Zhu H. Marcinkiewcz C. A. Michaelides M. Oshibuchi H. Rhea D. (2016 ). Elucidation of The behavioral program and neuronal network encoded by dorsal raphe serotonergic neurons. Neuropsychopharmacology 41 (5), 1404–1415.
Not in our library10.1038/npp.2015.293
212.
Verhoeyen E. Dardalhon V. Ducrey-Rundquist O. Trono D. Taylor N. Cosset F. L. (2003 ). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101 (6), 2167–2174.
Not in our library10.1182/blood-2002-07-2224
213.
Verlengia G. Miyagawa Y. Ingusci S. Cohen J. B. Simonato M. Glorioso J. C. (2017 ). Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. Sci. Rep. 7 (1), 1507.
Not in our library10.1038/s41598-017-01635-1
214.
Vogel R. Mammeri H. Mallet J. (2008 ). Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. Hum. Gene Ther. 19 (2), 167–178.
Not in our library10.1089/hum.2007.125
215.
Recombinant human myelin-associated glycoprotein promoter drives selective AAV-mediated transgene expression in oligodendrocytes · 2016
Not checked
216.
von Jonquieres G. Mersmann N. Klugmann C. B. Harasta A. E. Lutz B. Teahan O. (2013 ). Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One 8 (6), e65646.
Not in our library10.1371/journal.pone.0065646
217.
Von Seggern D. J. Kehler J. Endo R. I. Nemerow G. R. (1998 ). Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J. Gen. Virol. 79 (Pt 6), 1461–1468.
Not in our library10.1099/0022-1317-79-6-1461
218.
Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model · 2000
Not checked
219.
Wang C. Wang C. M. Clark K. R. Sferra T. J. (2003 a). Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 10 (17), 1528–1534.
Not in our library10.1038/sj.gt.3302011
220.
Wang D. Zhong L. Nahid M. A. Gao G. (2014 ). The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin. Drug Deliv. 11 (3), 345–364.
Not in our library10.1517/17425247.2014.871258
221.
Wang S. Petravicz J. Breakefield X. O. (2003 b). Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol. Ther. 7 (6), 790–800.
Not in our library10.1016/s1525-0016(03)00094-7
222.
West A. G. Gaszner M. Felsenfeld G. (2002 ). Insulators: many functions, many mechanisms. Genes Dev. 16 (3), 271–288.
Not in our library10.1101/gad.954702
223.
Wolff J. A. Rozema D. B. (2008 ). Breaking the bonds: Non-viral vectors become chemically dynamic. Mol. Ther. 16 (1), 8–15.
Not in our library10.1038/sj.mt.6300326
224.
Worgall S. Sondhi D. Hackett N. R. Kosofsky B. Kekatpure M. V. Neyzi N. (2008 ). Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19 (5), 463–474.
Not in our library10.1089/hum.2008.022
225.
Wu H. Lima W. F. Zhang H. Fan A. Sun H. Crooke S. T. (2004 ). Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279 (17), 17181–17189.
Not in our library10.1074/jbc.m311683200
226.
Wu N. Watkins S. C. Schaffer P. A. DeLuca N. A. (1996 ). Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70 (9), 6358–6369.
Not in our library10.1128/jvi.70.9.6358-6369.1996
227.
Wu Z. Miller E. Agbandje-McKenna M. Samulski R. J. (2006 ). Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80 (18), 9093–9103.
Not in our library10.1128/jvi.00895-06
228.
Xiong W. Goverdhana S. Sciascia S. A. Candolfi M. Zirger J. M. Barcia C. (2006 ). Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol. 80 (1), 27–37.
Not in our library10.1128/jvi.80.1.27-37.2006
229.
Yan Z. Zak R. Zhang Y. Engelhardt J. F. (2005 ). Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79 (1), 364–379.
Not in our library10.1128/jvi.79.1.364-379.2005
230.
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy · 2000
Not checked
231.
Yang B. Li S. Wang H. Guo Y. Gessler D. J. Cao C. (2014 ). Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol. Ther. 22 (7), 1299–1309.
Not in our library10.1038/mt.2014.68
232.
Yao S. Osborne C. S. Bharadwaj R. R. Pasceri P. Sukonnik T. Pannell D. (2003 ). Retrovirus silencer blocking by the cHS4 insulator is CTCF independent. Nucleic Acids Res. 31 (18), 5317–5323.
Not in our library10.1093/nar/gkg742
233.
Yee J. K. Miyanohara A. LaPorte P. Bouic K. Burns J. C. Friedmann T. (1994 ). A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 91 (20), 9564–9568.
Not in our library10.1073/pnas.91.20.9564
234.
Yew N. S. Wysokenski D. M. Wang K. X. Ziegler R. J. Marshall J. McNeilly D. (1997 ). Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum. Gene Ther. 8 (5), 575–584.
Not in our library10.1089/hum.1997.8.5-575
235.
Yizhar O. Fenno L. E. Davidson T. J. Mogri M. Deisseroth K. (2011 ). Optogenetics in neural systems. Neuron 71 (1), 9–34.
Not in our library10.1016/j.neuron.2011.06.004
236.
Yoon H. H. Min J. Hwang E. Lee C. J. Suh J. K. Hwang O. (2016 ). Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson’s disease. Stereotact. Funct. Neurosurg. 94 (1), 41–53.
Not in our library10.1159/000442891
237.
Yoon H. H. Park J. H. Kim Y. H. Min J. Hwang E. Lee C. J. (2014 ). Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease. Neurosurgery 74 (5), 533–540.
Not in our library10.1227/neu.0000000000000297
238.
Zahedi A. Defea K. Ethell I. (2013 ). Optogenetics to target actin-mediated synaptic loss in Alzheimer’s. Optogenetics: Optical Methods for Cellular Control 8586, 6.
Not in our library10.1117/12.2000480
239.
Zaupa C. Revol-Guyot V. Epstein A. L. (2003 ). Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum. Gene Ther. 14 (11), 1049–1063.
Not in our library10.1089/104303403322124774
240.
Zemelman B. V. Nesnas N. Lee G. A. Miesenbock G. (2003 ). Photochemical gating of heterologous ion channels: Remote control over genetically designated populations of neurons. Proc. Natl. Acad. Sci. U. S. A. 100 (3), 1352–1357.
Not in our library10.1073/pnas.242738899
241.
Zhang F. Frost A. R. Blundell M. P. Bales O. Antoniou M. N. Thrasher A. J. (2010 ). A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol. Ther. 18 (9), 1640–1649.
Not in our library10.1038/mt.2010.132
242.
Zhang H. Yang B. Mu X. Ahmed S. S. Su Q. He R. (2011 ). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19 (8), 1440–1448.
Not in our library10.1038/mt.2011.98
243.
Zhang S. Xu Y. Wang B. Qiao W. Liu D. Li Z. (2004 ). Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control. Release 100 (2), 165–180.
Not in our library10.1016/j.jconrel.2004.08.019
244.
Zhang W. Li L. Su Q. Gao G. Khanna H. (2018 ). Gene therapy using a miniCEP290 fragment delays photoreceptor degeneration in a mouse model of Leber congenital amaurosis. Hum. Gene Ther. 29 (1), 42–50.
Not in our library10.1089/hum.2017.049
245.
Zhou H. O’Neal W. Morral N. Beaudet A. L. (1996 ). Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J. Virol. 70 (10), 7030–7038.
Not in our library10.1128/jvi.70.10.7030-7038.1996
246.
Zhou X. Vink M. Klaver B. Berkhout B. Das A. T. (2006 ). Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther. 13 (19), 1382–1390.
Not in our library10.1038/sj.gt.3302780
247.
Zhu H. Pleil K. E. Urban D. J. Moy S. S. Kash T. L. Roth B. L. (2014 ). Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory. Neuropsychopharmacology 39 (8), 1880–1892.
Not in our library10.1038/npp.2014.35
248.
Zhu Y. J. Wienecke C. F. R. Nachtrab G. Chen X. K. (2016 ). A thalamic input to the nucleus accumbens mediates opiate dependence. Nature 530 (7589), 219–+.
Not in our library10.1038/nature16954

Cited by papers we hold 2

Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology · 2022
No notice
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.